Neurocrine Biosciences P/E Ratio

Neurocrine Biosciences (NBIX) currently reports a P/E ratio of 20.74. That is below the Healthcare sector average of 25.3. Use the charts on this page to explore Neurocrine Biosciences's P/E ratio history and peer comparisons.

Neurocrine Biosciences's P/E ratio of 20.74 is lower than the Healthcare sector average of 25.3. That is roughly 18.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Neurocrine Biosciences's market price to a fundamental measure such as earnings, sales, or book value. At 20.74, NBIX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 20.74, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.3. From there, open related valuation or income-statement pages for Neurocrine Biosciences, and consider following NBIX for alerts when major investors trade the stock.

Neurocrine Biosciences is classified in the Healthcare sector. On P/E ratio, it currently shows 20.74 versus a sector average near 25.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NBIX with unrelated industries.